Global Spasticity Therapeutics Poised for Major Evolution: DelveInsight Reveals Analysis of 12+ Pipeline Candidates

DelveInsight's newly published report, "Spasticity Pipeline Insight" delivers a comprehensive analysis of over 10 pharmaceutical and biotech companies actively developing more than 12 potential therapies across the Spasticity treatment pipeline. The report features in-depth profiles of both clinical- and preclinical-stage assets, supported by a detailed evaluation based on therapy type, stage of development, route of administration, and molecular classification. It also provides visibility into terminated and dormant programs within the Spasticity space.

Stay ahead of emerging trends in Spasticity treatment. Access DelveInsight's in-depth Spasticity Pipeline Report to explore novel therapies, prominent developers, and shifting dynamics within the treatment landscape. Discover more here - Spasticity Pipeline Outlook: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Spasticity Pipeline Report
• July 2025: Celgene initiated a Phase II clinical trial to assess the safety, effectiveness, and tolerability of three oral dose levels of BMS-986368, a dual FAAH/MAGL inhibitor, for treating Spasticity in patients with Multiple Sclerosis under the BALANCE-MSS-1 study.
• June 2025: Ipsen commenced a dose-escalation study of IPN10200 to evaluate its pharmacodynamic characteristics and establish the dose that offers the optimal balance between efficacy and safety in adults with upper limb spasticity.
• The report presents a robust and evolving pipeline landscape, featuring more than 10 active companies advancing over 12 innovative therapeutic programs for Spasticity.
• Key industry participants include Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd., Ipsen, Motor Pharma, Lundbeck A/S, among others.
• Prominent emerging therapies highlighted in the report include IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, and ultrasound-guided Meditoxin®.

Explore breakthroughs redefining Spasticity management. Gain full access to the clinical pipeline and ongoing study insights here: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spasticity Understanding: An Overview
Spasticity is a neurological motor condition marked by heightened muscle tone, rigidity, and involuntary muscle contractions caused by impaired signaling between the brain, spinal cord, and muscles. It frequently develops as a consequence of neurological disorders such as stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, and spinal cord injury. Persistent muscle stiffness can significantly restrict movement, hinder daily functioning, and diminish quality of life. Clinical severity ranges from mild muscle tightness to severe, painful spasms. Current management strategies include physiotherapy, oral pharmacological agents, botulinum toxin injections, and advanced options like intrathecal drug delivery. Ongoing research efforts focus on creating more precise, durable, and effective treatment approaches.

Emerging Drug Profiles in the Spasticity Pipeline
MELPIDA - Elpida Therapeutics SPC
Elpida Therapeutics SPC, a Social Purpose Corporation, specializes in developing gene therapies for ultra-rare pediatric neurological disorders. Its lead candidate, Melpida, is an AAV9-based gene therapy designed to deliver a functional AP4M1 gene via intrathecal administration for the treatment of SPG50. Following the completion of Phase I/II trials, the therapy has received FDA approval to advance into a Phase III study involving eight pediatric patients starting in August 2024. In addition to SPG50, Elpida is progressing gene therapy programs targeting disorders such as CMT4J. Melpida is currently in Phase III development.

SL-1002 - Saol Therapeutics
SL-1002 is a proprietary chemoneurolytic injectable therapy being investigated for the treatment of adult limb spasticity and pain associated with knee osteoarthritis. The candidate is presently undergoing Phase II clinical evaluation for Spasticity.

IPN-10200 - Ipsen
IPN-10200 is a next-generation, long-acting botulinum neurotoxin type A (mrBoNT/A) engineered to provide extended therapeutic duration. Delivered via intramuscular injection, the therapy is in Phase I/II clinical development for aesthetic indications such as glabellar and forehead lines, as well as for adult upper limb spasticity following stroke or traumatic brain injury. Ongoing studies are focused on assessing its safety, clinical benefit, and optimal dosing strategy.

What the Spasticity Pipeline Report Includes
• Detailed profiles of companies engaged in Spasticity drug development, along with the number of active programs under each organization.
• Categorization of pipeline assets by development stage, including early-, mid-, and late-stage programs.
• Overview of ongoing as well as paused or discontinued development efforts.
• Comprehensive analysis of therapies based on development phase, administration route, mechanism of action, molecular structure, and use as monotherapy or combination therapy.
• In-depth insights into strategic collaborations, licensing deals, and financial activities shaping pipeline advancement.

Uncover deeper insights into innovative programs driving progress in Spasticity care.
Explore the complete report - Spasticity Unmet Needs: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies Advancing the Spasticity Pipeline
Elpida Therapeutics SPC | Saol Therapeutics | Revance Therapeutics Inc. | BlackfinBio Ltd | Ipsen | Motor Pharma | Lundbeck A/S | Others

Spasticity Pipeline Segmentation by Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Spasticity Pipeline Segmentation by Molecule Type
• Monoclonal Antibodies
• Small Molecules
• Peptides

Gain actionable intelligence on upcoming therapies and critical development milestones.
Explore Spasticity market drivers, challenges, and future projections: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Spasticity Pipeline Report
• Geographic Coverage: Global
• Key Companies: Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd, Ipsen, Motor Pharma, Lundbeck A/S, and others
• Key Pipeline Assets: IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, ultrasound-guided Meditoxin®, among others
• Therapeutic Approaches: Monotherapy, Combination therapy, and Hybrid regimens
• Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III

Identify the leading innovators and breakthrough programs shaping Spasticity drug development.
Explore emerging therapies and the companies defining the future of care: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.